Europe's narrow path between the U.S. and China: Europe has an opening to become biotech's third pole, says Franck Le Deu in a BioCentury Guest Commentary, but only if it engages China while anchoring IP, manufacturing, development at home (open access): https://t.co/NS7WLaLWIZ
U.S. government's decision to brand WuXi AppTec a Chinese military co signals Trump admin intends to treat life sciences as a national security front, says BioCentury's @steveusdin1. Bipartisan will in Washington to reduce U.S. dependence on China's biopharma sector is strong.
More jitters in Washington as congressional concern grows over integration of China, U.S. biopharma. Legislation to limit in-licensing, add biotech to outbound investment controls pressures Trump to curtail biopharma engagement w China, says @steveusdin1 https://t.co/to6ox2lLuh
China NMPA priority rev in gastric cancer for Innovent's arcotatug tavatecan (IBI343) --> world's 1st CLDN18.2 ADC to be accepted for regulatory review h/t @BioBonanos
Atlas-to-therapy push by @AllenInstitute in neurodegeneration: Brain Health Accelerator, debuting with $400M, aims to turn cellular maps and disease data into precision gene therapies for neurodegeneration. Via @DanielleGolovin in @bioCentury: https://t.co/pO4EMsexnT
Biopharma companies, investors and patient advocates have grounds for believing that @US_FDA decisions under Makary, Prasad that appeared final a few months ago may be reversed, says @steveusdin1 https://t.co/soTo7BFeU4
.@WHOMB's Russell Vought has poured gas on the foundations of science. Pharma CEOs should demand that President Donald Trump take away the matches, writes @steveusdin1 (open access): https://t.co/V0zTZMb0zV
If half the time spent on hysteria about China in the U.S. went to competing on merits, biotechs and patients would be much better served, write my colleagues @BioPharmaJosh & @FishburnSimone. Open access: https://t.co/rVcrBlUrx2
A bit of everything this week, as @LaurenMMartz talks Revolution & more #ASCO26 insights, Tierney Baum geeks out on new ADC linker tech & @steveusdin1 breaks down China hawks push to set up biotech barriers.
Hengrui's Frank Jiang told me that his co's 13-program deal with $BMY is its 1st co-devel/co-comm deal with a Western biopharma, “another critical milestone on Hengrui’s globalization journey.” From NewCos to GSK, H has done some of the most interesting cross-border deals of late
Marty Makary won't be missed as @US_FDA commissioner, writes @steveusdin1. Now the Trump administration must decide whether and how to right the ship in the wake of his disastrous tenure https://t.co/hXgWiQ1kNZ
Top internal @US_FDA candidates for acting commissioner: Grace Graham, deputy commish for policy, legislation, international affairs; Lowell Zeta, deputy commish for strategic initiatives; Kyle Diamantas, deputy commish for human foods. via @Steveusdin1 https://t.co/yGGYdLFOfV